The Top Ten Things to Consider When Responding to a Threat of IP Litigation

Commercial Trial Law

Legal Blog by Mazin A. Sbaiti, ESQ || Dallas ,Texas

  • About Mazin Sbaiti
    • Practice Areas
  • Media
  • Antitrust
  • Contracts
  • Copyright
  • Fraud
  • Intellectual Property
  • Litigation
  • Patents
  • Securities and Investor
  • Trade Secrets

Judge Dismisses Securities Class Action Finding that Management “Genuinely Believed” Its Financial Projections

January 29, 2015 Fraud, Securities and Investor

A New York federal court threw out two securities class actions against French Drug manufacturer Sanofi. Investors claimed they were misled by Sanofi’s optimistic financial projections stemming from its drug “Lemtrada”– which had been developed by Genzyme (recently acquired by Sanofi). The court found that Sanofi’s executives genuinely believed their projections because they had been unaware of latent regulatory concerns surrounding Lemtrada. Once those concerns came to Sanofi’s attention, the story goes, they corrected their disclosures.

Generally, under an SEC safe harbor provision, a company is allowed to make forward looking statements without the risk of liability if those statements are couched in terms that they are forward looking statements, subject to risks and unknown contingencies, even if the projection does not come to be. Sanofi hung its hat on this provision of the safe harbor and the judge apparently agreed. While negligence is not typically grounds for fraud under the securities laws, recklessness is–as is reckless avoidance of the truth. It is unclear whether plaintiffs had access to such evidence which otherwise might have kept the case alive (e.g., if they could show that Sanofi ‘should have known’ about the regulatory risks).

The case is In re Sanofi Securities Litigation, case numbers 1:13-cv-08806 and 1:14-cv-02211, in the U.S. District Court for the Southern District of New York. For more information, contact Dallas Securities class action attorney Mazin A. Sbaiti, Esq. at Mazin@StecklerLaw.com or at (214) 432-2899.

Mazin A. Sbaiti

About the Author

Medium-sized and large businesses, entrepreneurs and sophisticated investors seek out Mazin Sbaiti for his aggressive, strategic and often unorthodox approach to litigation matters. Mr. Sbaiti...Read more about Mazin A. Sbaiti

Topics

  • Antitrust
  • Contracts
  • Copyright
  • Director & Officer
  • Fraud
  • Intellectual Property
  • Litigation
  • Media
  • Patents
  • Securities and Investor
  • Trade Dress
  • Trade Secrets
  • Uncategorized

Recent Posts

  • Sbaiti & Co. Makes it into Law360 Article About Impact of Universal Health Services v. Escobar on False Claims Act Litigation August 29, 2017
  • New Article [Tries to] Explain Why You’re Paying High Legal Fees… July 18, 2017
  • Eastern District of Texas Not Going Away as Patent Venue–But One Question Remains After TC Heartland, Raytheon July 8, 2017

Receive fresh content straight to your inbox

  • Google+
  • LinkedIn
  • YouTube

Contact Details

Mazin A. Sbaiti
917-698-9530
mazin@commercialtriallaw.com
  • Disclaimer
  • Privacy Policy

Information

Mr. Sbaiti has tried over twenty five matters to conclusion, and has recovered over $1 billion in damages for plaintiffs while saving defendants over $1.5 billion in liabilities.

About Mazin SbaitiPractice Areas

© 2019 All Rights Reserved|Commercial Trial Law|Log in|Created by Sheley Marketing
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.AcceptRead more